The present disclosure is directed to spherical nucleic acids (SNAs) comprising a nanoparticle core and an oligonucleotide, use of the SNAs to, e.g., detect target analytes, and methods of making the SNAs. In various embodiments, the target analyte is detected using the nanoparticle core, the oligonucleotide, or both. In some embodiments, the oligonucleotide comprises a detectable marker situated at an internal location within the oligonucleotide. In some aspects, the disclosure provides methods for detecting a target analyte comprising the step of contacting the target analyte with a spherical nucleic acid (SNA) and an agent, the SNA comprising a protein core and an oligonucleotide attached thereto, wherein the contacting of the protein core with the target analyte results in a change in the target analyte that is detectable by the agent, thereby detecting the target analyte.

Methods and systems for identifying and/or quantifying polypeptide binding interactions of ligand-binding polypeptides are disclosed. Detailed methods include methods for identifying binding ligands of ligand-binding polypeptides and methods for assessing changes in binding behavior due to alterations of ligand-binding polypeptides. Detailed systems include array-based systems that permit detection of ligand binding interactions at single-analyte resolution.

Methods and systems for identifying and/or quantifying polypeptide binding interactions of ligand-binding polypeptides are disclosed. Detailed methods include methods for identifying binding ligands of ligand-binding polypeptides and methods for assessing changes in binding behavior due to alterations of ligand-binding polypeptides. Detailed systems include array-based systems that permit detection of ligand binding interactions at single-analyte resolution.

Disclosed herein are detection devices, systems, and methods that use magnetic nanoparticles (MNPs) to allow molecules to be identified. Embodiments of this disclosure include magnetic sensors (e.g., magnetoresistive sensors) that can be used to detect temperature-dependent magnetic fields (or changes in magnetic fields) emitted by MNPs, and, specifically to distinguish between the presence and absence of magnetic fields emitted, or not emitted, by MNPs at different temperatures selected to take advantage of knowledge of how the MNPs' magnetic properties change with temperature. Embodiments disclosed herein may be used for nucleic acid sequencing, such as deoxyribonucleic acid (DNA) sequencing.

Disclosed herein are detection devices, systems, and methods that use magnetic nanoparticles (MNPs) to allow molecules to be identified. Embodiments of this disclosure include magnetic sensors (e.g., magnetoresistive sensors) that can be used to detect temperature-dependent magnetic fields (or changes in magnetic fields) emitted by MNPs, and, specifically to distinguish between the presence and absence of magnetic fields emitted, or not emitted, by MNPs at different temperatures selected to take advantage of knowledge of how the MNPs' magnetic properties change with temperature. Embodiments disclosed herein may be used for nucleic acid sequencing, such as deoxyribonucleic acid (DNA) sequencing.

Comparison of common sequencing reads from sequencing based on partition-based barcoding can be used to improve sequencing results. Increased loading of barcodes per partition can also improve sequencing results.

The present invention relates to a method for lysing pathogen lysis and a method for extracting nucleic acid using zinc oxide nanostar, and the method for extracting nucleic acid using zinc oxide nanostar according to the present invention can extract nucleic acids by lysing cells of a pathogen without using a lysis buffer and can extract nucleic acid of high-purity and high-concentration by preventing nucleic acid degradation and fragmentation through various substances including salts contained in the lysis buffer at high concentration. In addition, the zinc oxide nanostar of the present invention (200 to 900 nm) has superior cell lysis capacity compared to the conventional zinc oxide nanoparticles (20 to 50 nm), thereby increasing the nucleic acid extraction efficiency and can extract at room temperature without a heating step to use as a field diagnostic method.

The present invention relates to a method for lysing pathogen lysis and a method for extracting nucleic acid using zinc oxide nanostar, and the method for extracting nucleic acid using zinc oxide nanostar according to the present invention can extract nucleic acids by lysing cells of a pathogen without using a lysis buffer and can extract nucleic acid of high-purity and high-concentration by preventing nucleic acid degradation and fragmentation through various substances including salts contained in the lysis buffer at high concentration. In addition, the zinc oxide nanostar of the present invention (200 to 900 nm) has superior cell lysis capacity compared to the conventional zinc oxide nanoparticles (20 to 50 nm), thereby increasing the nucleic acid extraction efficiency and can extract at room temperature without a heating step to use as a field diagnostic method.

Described herein are systems and methods that may be used to differentially detect viral serotype specific nucleic acid. For example, these systems may comprise multiple DNA-nanostructures, capture oligonucleotides and protector oligonucleotides, wherein each DNA-nanostructure and its associated capture oligonucleotide and protector oligonucleotide are specific for a unique viral type or serotype.

Described herein are systems and methods that may be used to differentially detect viral serotype specific nucleic acid. For example, these systems may comprise multiple DNA-nanostructures, capture oligonucleotides and protector oligonucleotides, wherein each DNA-nanostructure and its associated capture oligonucleotide and protector oligonucleotide are specific for a unique viral type or serotype.